However, no potent and selective TLK2 inhibitors have been developed.<h4>Methods</h4>We evaluated the efficacy of a human TLK2 antisense oligonucleotide (ASO) alone and in combination with gilteritinib in AML cell lines. This evidence concerns the gene TLK2 and acute myeloid leukemia.